NasdaqCM - Delayed Quote USD

Artelo Biosciences, Inc. (ARTL)

1.3700 -0.0900 (-6.16%)
At close: May 28 at 4:00 PM EDT
1.4100 +0.04 (+2.92%)
After hours: May 28 at 5:30 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
8/31/2021
8/31/2020
8/31/2019
Operating Expense
10,227.0000
9,930.0000
10,287.0000
7,441.0000
4,686.0000
--
Operating Income
-10,227.0000
-9,930.0000
-10,287.0000
-7,441.0000
-4,686.0000
--
Net Non Operating Interest Income Expense
2.0000
--
-3.0000
2.0000
1.0000
--
Other Income Expense
623.0000
641.0000
207.0000
2.0000
30.0000
--
Pretax Income
-9,604.0000
-9,289.0000
-10,083.0000
-7,437.0000
-4,655.0000
--
Net Income Common Stockholders
-9,604.0000
-9,289.0000
-10,083.0000
-7,437.0000
-4,655.0000
--
Diluted NI Available to Com Stockholders
-9,604.0000
-9,289.0000
-10,083.0000
-7,437.0000
-4,655.0000
--
Basic EPS
-3.16
--
-3.56
-5.97
-18.90
-15.00
Diluted EPS
-3.16
--
-3.56
-5.97
-18.90
-15.00
Basic Average Shares
3,045.2500
--
2,833.0000
1,245.0000
247.1760
144.8310
Diluted Average Shares
3,045.2500
--
2,833.0000
1,245.0000
247.1760
144.8310
Total Operating Income as Reported
-10,227.0000
-9,930.0000
-10,287.0000
-7,441.0000
-4,686.0000
--
Total Expenses
10,227.0000
9,930.0000
10,287.0000
7,441.0000
4,686.0000
--
Net Income from Continuing & Discontinued Operation
-9,604.0000
-9,289.0000
-10,083.0000
-7,437.0000
-4,655.0000
--
Normalized Income
-10,227.0000
-9,930.0000
-10,290.0000
-7,439.0000
-4,685.0000
--
Interest Income
2.0000
--
2.0000
2.0000
1.0000
--
Interest Expense
--
--
5.0000
--
--
--
Net Interest Income
2.0000
--
-3.0000
2.0000
1.0000
--
EBIT
-9,586.0000
-9,289.0000
-10,078.0000
-7,437.0000
-4,686.0000
--
EBITDA
-9,586.0000
-9,289.0000
-10,078.0000
-7,437.0000
-4,686.0000
--
Reconciled Depreciation
--
--
--
--
0.5000
0.5100
Net Income from Continuing Operation Net Minority Interest
-9,604.0000
-9,289.0000
-10,083.0000
-7,437.0000
-4,655.0000
--
Total Unusual Items Excluding Goodwill
623.0000
641.0000
207.0000
2.0000
30.0000
--
Total Unusual Items
623.0000
641.0000
207.0000
2.0000
30.0000
--
Normalized EBITDA
-10,209.0000
-9,930.0000
-10,285.0000
-7,439.0000
-4,716.0000
--
8/31/2019 - 6/21/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SLRX Salarius Pharmaceuticals, Inc.
0.4641
-4.07%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.7200
-2.43%
 
VCNX Vaccinex, Inc.
5.01
-10.05%
 
CWBR CohBar, Inc.
0.7601
-13.62%
 
EMMA Emmaus Life Sciences, Inc.
0.0949
+3.00%
 
INM InMed Pharmaceuticals Inc.
0.2875
-5.21%
 
METX.CN METheraHld
3.9900
0.00%
 
QLGN Qualigen Therapeutics, Inc.
0.2820
-7.54%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.6200
-1.82%
 
CHRO Chromocell Therapeutics Corporation
1.3600
-5.17%